Casdin Capital’s Stoke Therapeutics STOK Stock Holding History

Casdin Capital’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-120,000	Closed	-$2.88M	–	53
2021 Q4	$2.88M	Hold	120,000	–	–	0.08%	51
2021 Q3	$3.05M	Hold	120,000	–	–	0.08%	51
2021 Q2	$4.04M	Hold	120,000	–	–	0.1%	51
2021 Q1	$4.66M	Hold	120,000	–	–	0.14%	45
2020 Q4	$7.43M	Hold	120,000	–	–	0.22%	47
2020 Q3	$4.02M	Hold	120,000	–	–	0.18%	44
2020 Q2	$2.86M	Hold	120,000	–	–	0.17%	42
2020 Q1	$2.75M	Sell	120,000 -10,000	-8%	-$247K	0.29%	38
2019 Q4	$3.68M	Hold	130,000	–	–	0.34%	32
2019 Q3	$2.79M	Buy	130,000 +45,000	+53%	+$1.25M	0.29%	33
2019 Q2	$2.48M	Buy	+85,000	New	+$2.28M	0.23%	29

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Casdin Capital's STOK Position: Q1 2022 in Review

Casdin Capital sold out of Stoke Therapeutics (STOK) in Q1 2022, closing a stake of 120,000 shares — an estimated $2.88M sold.

Casdin Capital first reported a position in STOK in Q2 2019 and held it in 11 quarters. The position peaked at $7.43M in Q4 2020. 99 funds tracked by Wall St. Rank hold STOK as of Q1 2022.

Casdin Capital reported no remaining Stoke Therapeutics position as of Q1 2022 after selling out during the quarter.
Casdin Capital sold 120,000 Stoke Therapeutics shares in Q1 2022, an estimated $2.88M.
Casdin Capital first reported a position in Stoke Therapeutics in Q2 2019 and held it in 11 quarters.
Casdin Capital's Stoke Therapeutics position peaked at $7.43M in Q4 2020.
99 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2022.

Based on Casdin Capital's 13F filing for Q1 2022, filed 16 May 2022.